PDT TREATMENT OF THE PROSTATE

前列腺 PDT 治疗

• 批准号: 2147540
• 负责人: DANIEL R DOIRON
• 金额: $ 10万
• 依托单位: PDT SYSTEMS
• 依托单位国家: 美国
• 财政年份: 1995
• 资助国家: 美国
• 起止时间: 1995-03-01 至 1995-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2147540
• 关键词: benign prostate hyperplasia; biological transport; dogs; neoplasm /cancer photoradiation therapy; nonhuman therapy evaluation; pharmacokinetics; prostate neoplasms; ultrasonography; urethra; urinary bladder

The two main clinical dysfunctions of the prostate are benign prostatic hypertrophy and malignant disease. A number of innovative approaches to treat these diseases have been introduced over the last decade to try and replace the TURP and intraoperative surgical approaches. These include pharmacological manipulation through alpha-blockers, balloon dilatation, laser thermal ablation, focused ultrasound and transrectal or transurethral hyperthermia for BPH, and cryosurgical ablation under ultrasound guidance for carcinoma of the prostate. Photodynamic Therapy is a relatively new form of treatment for cancer and other hyper- proliferating tissues that uses a photoactivating drug and light to selectively destroy the targeted tissue. it has been recently shown by Selman that the prostate of older dogs selectively takes up and retains the second generation photosensitizer SnET2 relative to the urethra and bladder. Such selective uptake raises the possibility of generating selective photochemical coagulation of the central portion of the prostate while not producing serious negative physiological consequences. Preliminary studies in the dog have shown this to be possible. It is the objective of this project to expand the pilot study of the concept. This is to include the development of a transurethral balloon based diffused delivery system that can be used in the dog. The delivery system includes a dosimetry monitors at the urethra/balloon interface for accurate in- vivo dosimetry. Also interstitial illumination using cylindrical diffusers will be studied. The systems will be tested in dogs to determine their in-vivo performance along with determination of the optical characteristics of the prostate and to further evaluate the potential for generating selective necrosis of the gland. PROPOSED COMMERCIAL APPLICATION: If it is found that PDT could effectively treat BPH, or prostate cancer, the commercial potential for the technology being developed under this project would be significant. For BPH such a treatment could be done on an outpatient or office bases compared to the present TURP requiring hospitalization. At present there are 360,000 TURP procedures done annually in the USA for BPH at an average cost of $8,606 and 40,000 radical prostatectomies for cancer and BPH at an average cost of $12,788. It is estimated that PDT transurethral procedure could be performed at a cost of $2,800.

前列腺的两种主要临床功能障碍是良性前列腺 肥大和恶性疾病。若干创新办法， 在过去的十年里， 取代TURP和术中手术入路。这些包括 通过α-受体阻滞剂，球囊扩张， 激光热消融、聚焦超声和经直肠或 前列腺增生症的经尿道热疗和冷冻消融 前列腺癌的超声引导。光动力疗法 是一种相对较新的治疗癌症和其他超 利用光活化药物和光， 选择性地破坏目标组织。最近的研究表明， 老年狗的前列腺选择性地吸收和保留 相对于尿道的第二代光敏剂SnET 2， 膀胱这种选择性吸收提高了产生 选择性光化学凝聚的中心部分 前列腺，同时不产生严重的负面生理后果。 对狗的初步研究表明这是可能的。是 本项目的目标是扩大对这一概念的试点研究。这 包括开发一种基于经尿道球囊的扩散 可以在狗身上使用的输送系统。输送系统包括 在尿道/气囊接口处的剂量测定监测器用于准确地测量 体内剂量学也使用圆柱形间隙照明 将研究扩散器。该系统将在狗身上进行测试， 沿着测定其体内性能， 前列腺的光学特性，并进一步评估 可能导致腺体选择性坏死。 建议的商业应用：如果发现PDT可以 有效治疗BPH或前列腺癌， 在这个项目下开发的技术将是重要的。 对于BPH，这种治疗可以在门诊或办公室进行 与目前需要住院治疗的TURP相比。现时 在美国，每年有360，000例TURP手术用于BPH， 平均成本为8，606美元和40，000美元的癌症根治术， BPH平均费用为12，788美元。估计PDT经尿道 手术费用为2 800美元。